# Resmed Inc: Form 10-Q for the period ended Sep 30, 2025

- Company: [Resmed Inc](/companies/rmd.md) (CIK 943819)
- Form: 10-Q
- Filed: 2025-10-31
- Accepted by EDGAR: Oct 30, 2025, 20:01 ET
- Period: 2025-09-30
- Accession: 0000943819-25-000090
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/943819/000094381925000090/rmd-20250930.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/943819/000094381925000090/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2025-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2025-07-01 to 2025-09-30 | $1.34bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2025-07-01 to 2025-09-30 | $514.8m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2025-07-01 to 2025-09-30 | $820.8m | us-gaap:GrossProfit |
| Research and development | 3 months, 2025-07-01 to 2025-09-30 | $87.3m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2025-07-01 to 2025-09-30 | $259.2m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2025-07-01 to 2025-09-30 | $446.5m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2025-07-01 to 2025-09-30 | $98.3m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2025-07-01 to 2025-09-30 | $348.5m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2025-07-01 to 2025-09-30 | $2.37 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2025-07-01 to 2025-09-30 | $2.38 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2025-07-01 to 2025-09-30 | 146,899,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months, 2025-07-01 to 2025-09-30 | $457.3m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months, 2025-07-01 to 2025-09-30 | $43.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 3 months, 2025-07-01 to 2025-09-30 | $87.8m | us-gaap:PaymentsOfDividends |
| Share repurchases | 3 months, 2025-07-01 to 2025-09-30 | $150.0m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2025-09-30 | $1.38bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2025-09-30 | $3.63bn | us-gaap:AssetsCurrent |
| Total assets | at 2025-09-30 | $8.31bn | us-gaap:Assets |
| Current liabilities | at 2025-09-30 | $1.26bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2025-09-30 | $2.19bn | us-gaap:Liabilities |
| Long-term debt | at 2025-09-30 | $408.7m | us-gaap:LongTermDebt |
| Short-term borrowings | at 2025-09-30 | $259.9m | us-gaap:ShortTermBorrowings |
| Shareholders' equity | at 2025-09-30 | $6.12bn | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 1,494 characters.

**Purchases of equity securities.** The following table summarizes our purchases of common stock for the three months ended September 30, 2025:

| Period | Total Number of Shares Purchased | Average Price Paid per Share (USD) | Total Number of Shares Purchased as Part of Publicly Announced Programs | Maximum Number of Shares that May Yet Be Purchased Under the Program |
| --- | ---: | ---: | ---: | ---: |
| July 1 - 31, 2025 | — | $— | 43,925,747 | 10,790,266 |
| August 1 - 31, 2025 | 523,212 | 286.42 | 44,448,959 | 10,267,054 |
| September 1 - 30, 2025 | — | — | 44,448,959 | 10,267,054 |
| Total | 523,212 | $286.42 | 44,448,959 | 10,267,054 |

On February 21, 2014, our board of directors approved our current share repurchase program, authorizing us to acquire up to an aggregate of 20.0 million shares of our common stock. The program allows us to repurchase shares of our common stock from time to time for cash in the open market, or in negotiated or block transactions, as market and business conditions warrant and subject to applicable legal requirements. The share repurchase program may be accelerated, suspended, delayed or discontinued at any time at the discretion of our board of directors. All share repurchases after February 21, 2014 have been executed under this program. Since approval of the share repurchase program in 2014 through September 30, 2025, we have repurchased a total of 9.7 million shares under this repurchase program for an aggregate of $1.0 billion.

## Controls and procedures

As filed, 1,804 characters.

We maintain disclosure controls and procedures that are designed to provide reasonable assurance that information required to be disclosed in our reports made pursuant to the Securities Exchange Act of 1934, as amended, or the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and in reaching a reasonable level of assurance management necessarily was required to apply its judgment in evaluating the cost benefit relationship of possible controls and procedures.

As required by Rule 13a-15(b) of the Exchange Act, we carried out an evaluation, under the supervision and with the participation of our management, including our chief executive officer and chief financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based on the foregoing, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of September 30, 2025.

There has been no change in our internal control over financial reporting during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 404 characters.

The discussion of our business and operations should be read together with the risk factors contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2025, or the Annual Report, which was filed with the SEC and describe various material risks and uncertainties to which we are or may become subject. As of September 30, 2025, there have been no material changes to such risk factors.

Filed Oct 31, 2025.
Source: SEC EDGAR, the filing index for accession 0000943819-25-000090. Last ingested by Listed: Nov 10, 2026, 02:09 ET. No prices; not investment advice.